Hengrui Pharmaceuticals (600276.SH) subsidiary RSS0393 Latex approved to conduct clinical trials.

Tencent Finance App News, Hengrui Medicine (600276.SH) announced that its subsidiary, Ruishi Biopharmaceutical Co., Ltd., recently received the approved and issued "Drug Clinical Trial Approval Notice" for RSS0393 latex from the National Medical Products Administration, and will soon conduct clinical trials.